{"meta":{"query_hash":"7bfd0db550be","filters":{"venue":"Kidney Cancer"},"cohort_total":11,"direct_labels_cover":0,"predictions_cover":11,"exported":11,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/7bfd0db550be","api":"https://metacan.xera.ac/api/v1/cohort?venue=Kidney+Cancer"},"results":[{"id":"W2605821659","doi":"10.3233/kca-160002","title":"Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)","year":2017,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"Foundation Medicine; Astellas Pharma; Eisai; National Comprehensive Cancer Network; GlaxoSmithKline; Exelixis; Genentech; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Renal cell carcinoma; Medicine; Chromophobe cell; Oncology; Targeted therapy; Cancer; Internal medicine; Clear cell","score_opus":0.05602898733680911,"score_gpt":0.3205884367928813,"score_spread":0.2645594494560722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605821659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96117383,0.0062393364,0.000018989156,0.01965885,0.0008611743,0.0013503253,0.0074126325,0.000020784906,0.0032640875],"genre_scores_gemma":[0.9893741,0.0020626988,0.0008820061,0.004722827,0.00032403384,0.00046479292,0.0008150343,0.000056542674,0.0012979553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963819,0.0003312101,0.00094036775,0.00071431056,0.0011285451,0.00050365995],"domain_scores_gemma":[0.99597895,0.0006659077,0.0009195032,0.0018981616,0.00025927828,0.0002781821],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00081398984,0.00048603307,0.00081830245,0.00013092459,0.00026504858,0.00011354189,0.0011881324,0.00006842699,0.0012790097],"category_scores_gemma":[0.00044813773,0.00025992104,0.0003151698,0.0001818362,0.0003791791,0.00026912152,0.00018364885,0.0005601492,0.000025900283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007703631,0.002329659,0.44488263,0.00028583212,0.002783217,0.0017156935,0.011319158,0.0002687357,0.35014284,0.000069631176,0.17452288,0.003976133],"study_design_scores_gemma":[0.018406449,0.0003164218,0.67337406,0.00028911053,0.0009298189,0.00001819459,0.0005448525,0.00045195842,0.28850904,0.0000788471,0.01670488,0.00037634218],"about_ca_topic_score_codex":0.049679007,"about_ca_topic_score_gemma":0.0029463856,"teacher_disagreement_score":0.22849147,"about_ca_system_score_codex":0.0003870303,"about_ca_system_score_gemma":0.0015302291,"threshold_uncertainty_score":0.9999853},"labels":[],"label_agreement":null},{"id":"W2741346996","doi":"10.3233/kca-170010","title":"Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward","year":2017,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University","funders":"ECOG-ACRIN Cancer Research Group; European Association of Urology; American College of Radiology Imaging Network; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Perioperative; Nephrectomy; Oncology; Adjuvant therapy; Internal medicine; Clinical trial; Surgery; Immunotherapy; Chemotherapy; Kidney; Cancer","score_opus":0.07852159444762236,"score_gpt":0.39968673167374524,"score_spread":0.3211651372261229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741346996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026310929,0.9901512,0.000016743546,0.0015423726,0.000581217,0.003405407,0.00047674627,0.00002033234,0.003779662],"genre_scores_gemma":[0.00007323656,0.9890068,0.00004673663,0.00091136066,0.00031369433,0.0026343502,0.00014381771,0.00007782469,0.006792133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980246,0.00010163083,0.0006436967,0.00048787575,0.00026617906,0.00047605316],"domain_scores_gemma":[0.9986206,0.00007660027,0.0003086671,0.0007369087,0.00003121107,0.00022596732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028676365,0.00058973866,0.0019855383,0.00016020155,0.00026193654,0.00010332261,0.0002890316,0.00017893872,0.000632521],"category_scores_gemma":[0.00003393125,0.00030391244,0.000849223,0.00023948816,0.00018304297,0.00011433846,0.00001815578,0.0003620767,0.00003557982],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020838279,0.00009760275,0.000024695393,0.0042999806,0.0010109671,0.000085338324,0.0016882538,3.1248325e-7,0.0000055914697,0.000010774152,0.0019073308,0.9906608],"study_design_scores_gemma":[0.0028499612,0.00037687688,0.000040032264,0.022712277,0.0016342326,0.00008254757,0.00007549997,0.000008634015,0.000019570212,0.000006498469,0.9718605,0.0003333533],"about_ca_topic_score_codex":0.0024693008,"about_ca_topic_score_gemma":0.00063049584,"teacher_disagreement_score":0.9903274,"about_ca_system_score_codex":0.0014451116,"about_ca_system_score_gemma":0.003959899,"threshold_uncertainty_score":0.9999413},"labels":[],"label_agreement":null},{"id":"W2787239315","doi":"10.3233/kca-170020","title":"Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)","year":2018,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Pazopanib; Sunitinib; Axitinib; Sorafenib; Renal cell carcinoma; Internal medicine; Oncology; Everolimus; Temsirolimus; Proportional hazards model; Targeted therapy; Retrospective cohort study; Urology; Surgery; Cancer; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors","score_opus":0.05521137413412077,"score_gpt":0.3092914079217557,"score_spread":0.25408003378763494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787239315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966716,0.0017853986,0.000084866646,0.019813305,0.0010466629,0.00076419854,0.00268761,0.000040124905,0.0070618372],"genre_scores_gemma":[0.9836946,0.00058216497,0.0015404968,0.009086844,0.0013875783,0.00013725917,0.0011064511,0.000044553803,0.0024200596],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977309,0.00012671959,0.000561236,0.0006003182,0.0006023473,0.00037847992],"domain_scores_gemma":[0.99812156,0.00028276784,0.00021329772,0.0008180108,0.00022601993,0.00033836544],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038722003,0.00029346108,0.00036651958,0.00011373089,0.00008286448,0.000042990472,0.00034078053,0.00006220709,0.0022491636],"category_scores_gemma":[0.00029687004,0.00018765115,0.00012694675,0.0002476935,0.00021763779,0.000119380085,0.00010991476,0.00030569927,0.00016451473],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01916683,0.0015805257,0.14387839,0.00007539505,0.0010674131,0.0019708122,0.0063894656,0.000054486347,0.22614685,0.000096506395,0.5788256,0.020747738],"study_design_scores_gemma":[0.035826076,0.0014773803,0.1902698,0.0005127738,0.00046569112,0.00007377914,0.0004868008,0.0029874677,0.5107567,0.00019978768,0.25634003,0.0006037156],"about_ca_topic_score_codex":0.0090276515,"about_ca_topic_score_gemma":0.00128058,"teacher_disagreement_score":0.32248554,"about_ca_system_score_codex":0.00040318814,"about_ca_system_score_gemma":0.00087831577,"threshold_uncertainty_score":0.9986629},"labels":[],"label_agreement":null},{"id":"W2996252896","doi":"10.3233/kca-190075","title":"Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and <sup>99m</sup> Tc-MDP Bone Scan in a Prospective Clinical Trial","year":2019,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Renal cell carcinoma; Radiology; PET-CT; Clinical trial; Nuclear medicine; Computed tomography; Oncology; Internal medicine","score_opus":0.021984695673895376,"score_gpt":0.3223716724288983,"score_spread":0.3003869767550029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996252896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958883,0.000766771,0.000013480342,0.00027621328,0.00009063369,0.0019154025,0.00013624443,0.000020360996,0.0008925919],"genre_scores_gemma":[0.9982976,0.00004305021,0.00088240905,0.00037101906,0.00004990037,0.00012517518,0.000045724555,0.000026896112,0.0001582587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975882,0.00023226668,0.0006486689,0.00067390676,0.00046011023,0.00039684484],"domain_scores_gemma":[0.99865353,0.00018553466,0.00028198224,0.00037553223,0.00017551355,0.0003279273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005279034,0.00029051976,0.0013043795,0.00012739196,0.000038818325,0.0000073853785,0.00007982866,0.000022126458,0.000082726525],"category_scores_gemma":[0.00028819527,0.00017882125,0.000051724277,0.00034731248,0.0006939435,0.00008465659,0.000050743798,0.00061391847,0.0000024013884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05865893,0.0011097783,0.9368625,0.00022263388,0.00011114599,0.0004072499,0.00063115836,0.000033412893,0.000006949069,0.0000016271797,0.00070310413,0.0012514546],"study_design_scores_gemma":[0.13519749,0.0070953355,0.85438144,0.00083115615,0.00029825506,0.00005972028,0.0006410319,0.00044476823,0.00032207085,0.000006906149,0.0004778436,0.00024396699],"about_ca_topic_score_codex":0.0011749249,"about_ca_topic_score_gemma":0.00080217625,"teacher_disagreement_score":0.08248109,"about_ca_system_score_codex":0.000086966174,"about_ca_system_score_gemma":0.0007268774,"threshold_uncertainty_score":0.7292119},"labels":[],"label_agreement":null},{"id":"W2997361961","doi":"10.3233/kca-190077","title":"Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer","year":2019,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Dosing; Medicine; Toxicity; Vascular endothelial growth factor; Cancer; Drug; Tyrosine-kinase inhibitor; Adjuvant; Oncology; VEGF receptors; Pharmacology; Internal medicine","score_opus":0.0229485505792703,"score_gpt":0.3077115109704465,"score_spread":0.2847629603911762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997361961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351114,0.00048944715,0.00002676606,0.002641993,0.00026402422,0.0012058964,0.0003502695,0.00001918995,0.001491267],"genre_scores_gemma":[0.9934726,0.000104403865,0.0005989817,0.0045338706,0.00007822544,0.00029713017,0.0001334393,0.000030235246,0.0007511594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989151,0.000036341466,0.00023567662,0.0003144947,0.0002727167,0.00022568618],"domain_scores_gemma":[0.9991989,0.000048743685,0.00011074237,0.00023802703,0.000095233474,0.00030834632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016633223,0.00016551651,0.00035467176,0.00016055607,0.000022045666,0.000009339079,0.00005444589,0.000100538906,0.0007680557],"category_scores_gemma":[0.00012927265,0.00013823123,0.00006413238,0.00021306197,0.00004210291,0.00006434341,0.000020596966,0.00009518905,0.0000060596285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018990635,0.0004950278,0.94997835,0.0017098972,0.0001282716,0.0000050992753,0.0010900706,0.00036721007,0.028622529,0.0001936663,0.0076760426,0.00783477],"study_design_scores_gemma":[0.030936562,0.0019081826,0.6586628,0.0038576017,0.00042938543,0.0000026165292,0.00015798988,0.015127607,0.26412526,0.00014407153,0.024114627,0.0005333173],"about_ca_topic_score_codex":0.00093019585,"about_ca_topic_score_gemma":0.000082223385,"teacher_disagreement_score":0.29131556,"about_ca_system_score_codex":0.00037371457,"about_ca_system_score_gemma":0.0009133553,"threshold_uncertainty_score":0.84096706},"labels":[],"label_agreement":null},{"id":"W3014903654","doi":"10.3233/kca-190076","title":"First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Renal cell carcinoma; Medicine; Oncology; Nivolumab; Cancer research; Internal medicine; Immunotherapy; Cancer","score_opus":0.06481327969497024,"score_gpt":0.33528547229551825,"score_spread":0.270472192600548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014903654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000024490064,0.97242695,0.00016265581,0.002248002,0.00043474056,0.023491396,0.00093698053,0.000110862165,0.0001859607],"genre_scores_gemma":[0.000079381694,0.9717251,0.0009589338,0.0030275285,0.00061707746,0.020676825,0.0014044695,0.0003298828,0.0011808012],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99426854,0.0003850195,0.0027196403,0.0011429444,0.00078955444,0.00069431274],"domain_scores_gemma":[0.9950989,0.00041995887,0.0017327132,0.0014294882,0.00034233538,0.0009766431],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00067608844,0.001374465,0.009076879,0.0002461613,0.00012771756,0.000047048943,0.0004256538,0.000263916,0.0005419656],"category_scores_gemma":[0.0005913636,0.00088332593,0.0034846575,0.0007331476,0.00008063453,0.000055216013,0.00007408667,0.00061797054,0.00017209344],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011840579,0.00029743224,7.750463e-7,0.97798026,0.0009190047,0.0002620843,0.00003655994,0.0000010230135,0.000016395723,0.0000021391577,0.007766272,0.012599672],"study_design_scores_gemma":[0.0028551484,0.0008179264,6.1165167e-7,0.49366212,0.021844106,0.000076617674,0.0000027732685,0.00003342089,0.00046336377,0.0000030655754,0.47976026,0.000480615],"about_ca_topic_score_codex":0.00014776728,"about_ca_topic_score_gemma":0.000006824075,"teacher_disagreement_score":0.48431814,"about_ca_system_score_codex":0.0016999134,"about_ca_system_score_gemma":0.0049610836,"threshold_uncertainty_score":0.9999006},"labels":[],"label_agreement":null},{"id":"W3135371333","doi":"10.3233/kca-210110","title":"Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)","year":2021,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; St Joseph's Health Centre; University of Ottawa; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Toronto; Western University; Princess Margaret Cancer Centre; University of Calgary; Centre hospitalier universitaire de Québec; London Health Sciences Centre; Alberta Health Services; McMaster University; University of Manitoba; Juravinski Cancer Centre; Université Laval; University of Alberta","funders":"Genentech; Ipsen; Astellas Pharma; Eisai; Karyopharm Therapeutics; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Exelixis; GlaxoSmithKline","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Kidney cancer; Internal medicine; Cancer; Oncology; Tyrosine-kinase inhibitor; Population; Urology; Surgery; Gastroenterology","score_opus":0.027269369056509476,"score_gpt":0.27533422388788525,"score_spread":0.24806485483137578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135371333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718836,0.0013516133,0.0000061191104,0.004795017,0.0007326995,0.00081057684,0.003915533,0.000031692263,0.016473142],"genre_scores_gemma":[0.9947554,0.0003810527,0.00042267525,0.0022854917,0.00019147026,0.0003684856,0.00073822535,0.000031011292,0.00082618324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722946,0.0001790247,0.00094018836,0.0004425809,0.00065943523,0.00054934213],"domain_scores_gemma":[0.99724615,0.00012551842,0.00038181432,0.00083440635,0.000416204,0.0009958871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027927273,0.0003132404,0.00059458124,0.00018686862,0.00014408269,0.000056860015,0.00023598292,0.00012429927,0.00045761783],"category_scores_gemma":[0.00040259352,0.0002331971,0.00014498142,0.00075197907,0.000119301636,0.00026173686,0.00006387375,0.00030928457,0.000030673407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040717158,0.0003857704,0.62134296,0.0027369198,0.000819444,0.0030952636,0.11176465,0.000995275,0.04911506,0.0004606628,0.19324796,0.011964351],"study_design_scores_gemma":[0.012823508,0.00017890331,0.55111855,0.0030975677,0.00072706165,0.00007172352,0.008864079,0.0015018969,0.3296446,0.000011670358,0.09131582,0.00064465037],"about_ca_topic_score_codex":0.8798737,"about_ca_topic_score_gemma":0.4029926,"teacher_disagreement_score":0.47688112,"about_ca_system_score_codex":0.0019315255,"about_ca_system_score_gemma":0.010122112,"threshold_uncertainty_score":0.9954896},"labels":[],"label_agreement":null},{"id":"W3186123873","doi":"10.3233/kca-210116","title":"Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Nephrectomy; Medicine; Renal cell carcinoma; Clear cell renal cell carcinoma; Immunohistochemistry; Oncology; Proportional hazards model; Internal medicine; Kidney cancer; Cancer; Metastasis; Clear cell; Pathology; Kidney","score_opus":0.014673006305765644,"score_gpt":0.2340668076723973,"score_spread":0.21939380136663164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186123873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641633,0.0008912098,0.000005394983,0.00024617076,0.000093222836,0.00049532123,0.00013516955,0.000023829238,0.0016933533],"genre_scores_gemma":[0.9970073,0.000039065413,0.0006451822,0.00064110674,0.00003407997,0.00010272471,0.00027546185,0.0000678382,0.0011872603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771905,0.00018800347,0.0003432512,0.0005767332,0.0006753296,0.00049765065],"domain_scores_gemma":[0.99884033,0.000055324534,0.00015575526,0.00036490924,0.00021155427,0.0003721372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012285504,0.00032674745,0.0006125371,0.00016735587,0.000047320224,0.000028506247,0.00008702631,0.00007843861,0.0006490965],"category_scores_gemma":[0.000049399205,0.00023407253,0.000071253125,0.00061855285,0.00006436409,0.00011851027,0.000058581656,0.00024564078,0.000014374113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021079078,0.0011620119,0.9871246,0.00017327083,0.00004898091,0.0014113308,0.0009987247,0.000067252004,0.00581668,6.949562e-7,0.00095159304,0.00013692612],"study_design_scores_gemma":[0.02026195,0.0009909857,0.7908748,0.0007453487,0.0001677576,0.000006200919,0.000320225,0.00012152735,0.18597123,0.0000033893207,0.00025488593,0.00028174568],"about_ca_topic_score_codex":0.0011009622,"about_ca_topic_score_gemma":0.0005255798,"teacher_disagreement_score":0.19624987,"about_ca_system_score_codex":0.0013282002,"about_ca_system_score_gemma":0.0015382007,"threshold_uncertainty_score":0.9545201},"labels":[],"label_agreement":null},{"id":"W4200092447","doi":"10.3233/kca-210117","title":"Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Exelixis; University of Texas Southwestern Medical Center; Burroughs Wellcome Fund","keywords":"Cabozantinib; Medicine; Disease; Renal cell carcinoma; Cancer research; Oncology; Internal medicine; Urology; Pharmacology","score_opus":0.015818733380308158,"score_gpt":0.2664854274567906,"score_spread":0.25066669407648245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200092447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987016,0.0051562646,0.00007175124,0.0029551755,0.00014285854,0.00069416955,0.00043004507,0.000034913573,0.0034988027],"genre_scores_gemma":[0.99089575,0.000072658906,0.00065981835,0.0027764805,0.00015309885,0.00037559576,0.0003431472,0.000045808603,0.004677621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796414,0.00015990404,0.00035491833,0.00055540126,0.0005415254,0.00042409461],"domain_scores_gemma":[0.99801576,0.00007310572,0.00011505414,0.00044909568,0.00022981215,0.0011171693],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013670775,0.00028995983,0.00048953533,0.00013702705,0.000054640015,0.000026892232,0.00007401865,0.000041776275,0.0025778562],"category_scores_gemma":[0.00012225274,0.00022525329,0.0001695203,0.00037206567,0.00009317508,0.0000968413,0.000033764645,0.00022268742,0.000044136123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012643065,0.003373244,0.88971245,0.0012294787,0.00063175504,0.044089854,0.00034428766,0.00023453424,0.033240486,0.0003744967,0.011862108,0.002264265],"study_design_scores_gemma":[0.03000542,0.00034283087,0.9389495,0.0004601667,0.0013193998,0.00018766109,0.00009634701,0.0005268139,0.022179473,0.00013179137,0.0054346537,0.00036590293],"about_ca_topic_score_codex":0.0010379851,"about_ca_topic_score_gemma":0.00022883354,"teacher_disagreement_score":0.049237113,"about_ca_system_score_codex":0.0003592216,"about_ca_system_score_gemma":0.004082616,"threshold_uncertainty_score":0.99833393},"labels":[],"label_agreement":null},{"id":"W4396814048","doi":"10.3233/kca-230025","title":"Patient Selection for Active Surveillance for Small Renal Masses: A Systematic Review of the Literature","year":2024,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Concordance; Systematic review; Meta-analysis; Comorbidity; MEDLINE; Internal medicine; Cochrane Library; Oncology; Intensive care medicine","score_opus":0.03505213495838975,"score_gpt":0.3362367575413587,"score_spread":0.3011846225829689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396814048","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014455262,0.9775949,0.0000284971,0.00037488798,0.0006937155,0.018421028,0.0027263488,0.000027293127,0.0001318521],"genre_scores_gemma":[0.000005046336,0.9791305,0.0002818234,0.0006160424,0.00030336133,0.01690332,0.0005058787,0.00009307198,0.0021609375],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99784696,0.00020090934,0.0009170836,0.0004951958,0.0002880884,0.00025177634],"domain_scores_gemma":[0.9977402,0.00024033,0.0008433203,0.0005159097,0.0005101712,0.0001500534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029701638,0.00047354415,0.0028688237,0.000104558756,0.000049418024,0.000025453352,0.0001468351,0.00022560745,0.000022919108],"category_scores_gemma":[0.0008131215,0.00022799306,0.0016709473,0.0006066574,0.000026155882,0.00002328455,0.00004239197,0.00029957775,0.0000040458103],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039756287,0.000034971577,0.000001320594,0.9548911,0.0012619705,0.0000023096943,0.00009034105,7.116903e-8,0.0000023508708,0.000016106918,0.02228711,0.021372598],"study_design_scores_gemma":[0.0001684022,0.00017551819,3.9690318e-7,0.5610767,0.009068524,0.000054472453,0.0000032100265,0.0000035075057,0.000034897555,0.000008384137,0.4292961,0.00010985761],"about_ca_topic_score_codex":0.00001996404,"about_ca_topic_score_gemma":0.000018650506,"teacher_disagreement_score":0.407009,"about_ca_system_score_codex":0.0011120172,"about_ca_system_score_gemma":0.0019865022,"threshold_uncertainty_score":0.9297287},"labels":[],"label_agreement":null},{"id":"W4401252649","doi":"10.3233/kca-240005","title":"Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy","year":2024,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Calgary","funders":"Ipsen","keywords":"Cabozantinib; Renal cell carcinoma; Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Oncology; Internal medicine; Cancer research; Cancer; Receptor","score_opus":0.016508258337435484,"score_gpt":0.2769879987711579,"score_spread":0.2604797404337224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401252649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206674,0.0026723675,0.000010306395,0.0012736833,0.0006065361,0.0016086386,0.00023809112,0.00013813064,0.0013855282],"genre_scores_gemma":[0.990788,0.000136321,0.0013411208,0.0015171312,0.0002264734,0.0007616643,0.00008821243,0.00019566219,0.0049454034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701667,0.000101435195,0.00066722045,0.0008474827,0.000709844,0.0006573636],"domain_scores_gemma":[0.99850273,0.00011639143,0.00015479591,0.0005798208,0.00015094934,0.0004953207],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001881277,0.0006039942,0.0007597705,0.00054977037,0.000055937773,0.00007376978,0.000109037224,0.00008749072,0.0014765563],"category_scores_gemma":[0.000039524977,0.00037234413,0.000209188,0.0008827968,0.00011745139,0.00021319857,0.00003978246,0.00040555917,0.00004839484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058176364,0.000909731,0.97761697,0.00070711516,0.00013617681,0.00092355907,0.00063712534,0.000063743086,0.004138113,0.0000027008077,0.0023983591,0.0066487473],"study_design_scores_gemma":[0.01459476,0.0018292969,0.8464799,0.0030405135,0.00023189788,0.0000036795477,0.000047140667,0.00010438556,0.122756526,0.000007423117,0.010306652,0.0005978385],"about_ca_topic_score_codex":0.0016628595,"about_ca_topic_score_gemma":0.00086667866,"teacher_disagreement_score":0.1311371,"about_ca_system_score_codex":0.00092937046,"about_ca_system_score_gemma":0.0012234004,"threshold_uncertainty_score":0.99987286},"labels":[],"label_agreement":null}]}